查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951185

CRISPR和Cas基因市場－全球產業規模、佔有率、趨勢、機會及預測（按產品/服務、應用、最終用途、地區和競爭格局分類，2021-2031年）

CRISPR and Cas Genes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Application, By End-use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 CRISPR 和 Cas 基因市場預計將從 2025 年的 29.1 億美元成長到 2031 年的 74.6 億美元，複合年成長率為 16.98%。

此領域涵蓋基因組編輯解決方案的開發和推廣，這些方案利用叢集規律間隔短回文重複序列（CRISPR）及其相關蛋白進行精確的DNA修飾。推動此市場發展的關鍵因素包括：需要治療的先天性遺傳疾病發生率不斷上升，以及農業生物技術在提高作物抗性方面的迫切需求。此外，政府和私人機構持續的資金投入為研發提供了必要的資源，使其不受瞬息萬變的技術潮流的影響，成為推動產業成長的根本動力。

市場概覽
預測期 2027-2031
市場規模：2025年 29.1億美元
市場規模：2031年 74.6億美元
複合年成長率：2026-2031年 16.98%
成長最快的細分市場 服務
最大的市場 北美洲

然而，該市場在這些治療方法的安全性方面面臨著許多挑戰，尤其是脫靶基因突變的風險，增加了監管核准流程的複雜性。這些技術難題需要嚴格且耗時的檢驗研究，可能會延遲治療應用的商業性推出。儘管存在這些障礙，該領域依然蓬勃發展。美國基因與細胞治療學會（ASGCT）指出，截至2024年，全球已有超過4,000種基因、細胞和RNA治療方法正在研發中。如此龐大的候選療法數量凸顯了市場對精準基因編輯解決方案的強勁需求，前提是這些方案能夠滿足可靠的安全性和監管標準。

市場促進因素

在生物技術產業，策略聯盟和夥伴關係已成為全球CRISPR和Cas基因市場商業化的關鍵驅動力，因為各公司都在尋求整合智慧財產權和資本，以應對複雜的法規環境。大型製藥企業擴大與專業的基因編輯公司達成許可協議，將後者的專有平台整合到開發平臺中，從而有效降低了早期研發階段的高昂成本和風險。例如，2024年10月，Editas Medicine宣布其與DRI Healthcare Trust的策略合作已獲得5,700萬美元的預付款，這筆款項預支了與Vertex Pharmaceuticals合作專案未來的許可費，從而增強了其營運資金。此類合作對於將學術發現轉化為可行的商業產品至關重要，並能幫助小規模的創新者獲得實現其商業目標所需的永續資金。

同時，提升CRISPR技術療效和安全性的技術進步解決了與脫靶效應和遞送系統相關的關鍵挑戰，擴大了其市場覆蓋範圍。體內編輯技術和先進遞送載體的進步使得在患者體內進行精準基因修飾成為可能，推動了該行業從體外應用向全身治療的轉變。臨床結果證實了這項轉變。 2024年11月，Intella Therapeutics宣布，美國食品藥物管理局（FDA）核准了該公司的臨床實驗（IND）申請，並啟動了一項針對50名遺傳性轉甲狀腺素類澱粉沉積症變性患者的單劑量體內療法的關鍵性3期臨床試驗。該領域能夠繼續進行此類高風險研究，得益於其雄厚的資金實力。截至2024年11月，Vertex Pharmaceuticals在第三季末擁有112億美元的現金和投資，為基因編輯藥物的持續創新提供了堅實的財務基礎。

市場挑戰

脫靶基因突變的風險已成為全球CRISPR和Cas基因市場面臨的重大阻礙因素，從根本上影響著該產業的成長速度。監管機構優先考慮病患安全，並要求提供全面的數據來檢驗基因編輯工具不會意外改變非標靶DNA序列。這項要求延長了臨床前檢驗階段，並顯著延緩了新療法候選藥物的研發進程。因此，生物技術公司在啟動人體臨床試驗之前，必須投入大量資源和時間進行全面的安全性評估，從而有效地減緩了從藥物發現到臨床應用的整個過程。

這些技術和監管障礙造成了漏斗效應，使得許多處於研發階段的資產難以快速獲得臨床試驗核准。這些嚴格的安全標準顯然阻礙了研發管線的進展。根據再生醫學聯盟的數據，到2024年，全球市場上正在進行的臨床試驗總數預計僅年增3%。這種溫和的成長率表明，與安全性相關的檢驗障礙直接限制了治療方法走向商業化的數量，最終阻礙了市場的整體成長。

市場趨勢

鹼基編輯技術的廣泛應用標誌著基因編輯技術向精準化邁出了重要一步，它能夠在不造成雙股DNA斷裂的情況下進行單鹼基替換。這項措施直接解決了傳統編輯技術相關的安全隱患，降低了染色體重排的風險，並擴大了敏感組織中基因修復的範圍。製造商正致力於利用這些先進平台開發針對複雜遺傳疾病（例如血紅蛋白病和α1-抗胰蛋白酶缺乏症）的根治性治療方法。根據Beam Therapeutics公司於2024年8月發布的“2024年第二季度財務業績報告”，該公司擁有雄厚的財務實力，並披露其擁有10億美元的現金和證券，用於拓展其鹼基編輯臨床研究項目。

將人工智慧應用於RNA設計指導，正在為療效預測和脫靶效應降低樹立新的標準。借助深度學習演算法，科學家可以分析龐大的基因組庫，並建立合成編輯系統，從而克服天然酵素的限制。這種計算策略顯著加快了發現階段，能夠在生物學檢驗之前快速識別出高精度的候選基因。在2024年4月發布的「OpenCRISPR-1」計畫中，Profluent公司利用基於110萬個基因組序列訓練的人工智慧模型，開發了首個開放原始碼的、性能可與傳統Cas9工具相媲美的AI基因編輯工具。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球CRISPR和Cas基因市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品/服務分類（產品（試劑盒/酵素、文庫、設計工具、抗體等）、服務（細胞株設計、gRNA 設計、微生物基因編輯、DNA 合成））
    • 按應用領域（生物醫學、農業）
    • 依最終用戶（生技/製藥公司、學術/政府研究機構、受託研究機構(CRO)）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美 CRISPR 和 Cas 基因市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲 CRISPR 和 Cas 基因市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區 CRISPR 和 Cas 基因市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲 CRISPR 和 Cas 基因市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美 CRISPR 和 Cas 基因市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章全球CRISPR 與 Cas 基因市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca plc
  • Addgene
  • Cellectis bioresearch Inc
  • CRISPR Therapeutics Inc.
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Horizon Discovery Group plc
  • Lonza Group AG
  • GenScript Biotech Corporation
  • Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23867

The Global CRISPR and Cas Genes Market is projected to expand from USD 2.91 Billion in 2025 to USD 7.46 Billion by 2031, reflecting a compound annual growth rate of 16.98%. This sector encompasses the creation and distribution of genome editing solutions that employ Clustered Regularly Interspaced Short Palindromic Repeats and related proteins to perform accurate DNA alterations. Key forces driving this market include the rising incidence of congenital genetic diseases requiring curative therapies and the urgent need for agricultural biotechnology to improve crop hardiness. Additionally, continuous financial investment from both government agencies and private institutions acts as a fundamental catalyst for industry growth, supplying essential resources for research and development independent of temporary technological trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.91 Billion
Market Size 2031USD 7.46 Billion
CAGR 2026-203116.98%
Fastest Growing SegmentService
Largest MarketNorth America

However, the market faces a major obstacle concerning the safety profile of these instruments, particularly the danger of off-target genetic mutations, which adds complexity to the regulatory approval pathway. This technical challenge requires strict, time-intensive validation studies that can postpone the commercial launch of therapeutic applications. Demonstrating the breadth of sector activity despite these impediments, the American Society of Gene & Cell Therapy noted that in 2024, the global landscape comprised over 4,000 gene, cell, and RNA therapies under development. This substantial number of candidates highlights the strong demand for precise gene editing solutions, contingent upon successfully meeting safety and regulatory benchmarks.

Market Driver

Strategic alliances and partnerships within the biotechnology industry are emerging as a primary catalyst for commercialization in the Global CRISPR and Cas Genes Market, as firms aim to combine intellectual property and capital to manage complex regulatory environments. Major pharmaceutical companies are increasingly signing licensing deals with specialized gene-editing enterprises to incorporate proprietary platforms into their development pipelines, effectively lowering the significant costs and risks linked to early-stage research. For example, according to Editas Medicine in October 2024, the firm bolstered its operating capital by obtaining a $57 million upfront payment via a strategic arrangement with DRI Healthcare Trust to monetize future license royalties stemming from its partnership with Vertex Pharmaceuticals. These collaborations are crucial for transforming academic discoveries into viable commercial products, ensuring that smaller innovators possess the enduring funding needed to attain commercial goals.

Concurrently, technological improvements that boost CRISPR effectiveness and safety are widening the market's reach by solving major problems regarding off-target effects and delivery systems. Breakthroughs in in vivo editing and advanced delivery vectors now permit precise genetic changes directly within the patient, advancing the industry beyond ex vivo uses toward systemic functional treatments. This evolution is illustrated by clinical achievements; according to Intellia Therapeutics in November 2024, the U.S. FDA approved the company's Investigational New Drug application to begin a crucial Phase 3 trial for a single-dose in vivo therapy involving 50 adults with hereditary transthyretin amyloidosis. The sector's ability to sustain such high-stakes research is supported by substantial capital holdings; according to Vertex Pharmaceuticals in November 2024, the company closed the third quarter with $11.2 billion in cash and investments, offering a strong financial foundation for ongoing innovation in gene-edited medicines.

Market Challenge

The danger of off-target genetic mutations acts as a significant constraint for the Global CRISPR and Cas Genes Market, fundamentally affecting the speed of industry growth. Regulatory authorities, placing a premium on patient safety, require comprehensive data to verify that editing instruments do not accidentally modify non-target DNA sequences. This stipulation mandates extended preclinical validation stages, which considerably lengthens the development timeline for new therapeutic hopefuls. As a result, biotechnology companies must dedicate substantial capital and time to thorough safety profiling prior to commencing human trials, effectively delaying the progression from initial discovery to clinical implementation.

This technical and regulatory barrier generates a funnel effect, wherein a large quantity of research-stage assets faces difficulty in rapidly obtaining approval for clinical entry. The consequence of these strict safety criteria is apparent in the stalling of pipeline advancement. According to the Alliance for Regenerative Medicine, in 2024, the global sector registered only a 3% year-over-year rise in the total number of active clinical trials. This slight growth rate illustrates how safety-related validation hurdles directly limit the quantity of therapies progressing toward commercialization, thereby impeding the overall growth trajectory of the market.

Market Trends

The uptake of base editing technologies marks a crucial evolution toward precision, allowing for single-base alterations without causing double-strand DNA breaks. This movement directly tackles safety issues linked to conventional editing techniques by reducing the chance of chromosomal rearrangements, thus broadening the utility of gene correction for sensitive tissues. Manufacturers are intensely focusing on these sophisticated platforms to create curative therapies for intricate genetic disorders like hemoglobinopathies and alpha-1 antitrypsin deficiency. According to Beam Therapeutics in August 2024, in its 'Second Quarter 2024 Financial Results', the firm announced a robust balance sheet featuring $1.0 billion in cash and marketable securities to further its portfolio of base editing clinical initiatives.

The incorporation of artificial intelligence into guide RNA formulation is creating a new standard for predicting efficacy and minimizing off-target events. By utilizing deep learning algorithms, scientists can now examine vast genomic libraries to construct synthetic editing systems that overcome the constraints of naturally occurring enzymes. This computational strategy notably hastens the discovery stage, enabling the swift recognition of high-fidelity candidates before biological validation occurs. According to Profluent in April 2024, in the 'OpenCRISPR-1 Announcement', the enterprise employed an AI model trained on 1.1 million genomic sequences to produce the first open-source, AI-designed gene editor that rivals the performance of conventional Cas9 instruments.

Key Market Players

  • AstraZeneca plc
  • Addgene
  • Cellectis bioresearch Inc
  • CRISPR Therapeutics Inc.
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Horizon Discovery Group plc
  • Lonza Group AG
  • GenScript Biotech Corporation
  • Merck KGaA

Report Scope

In this report, the Global CRISPR and Cas Genes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CRISPR and Cas Genes Market, By Product & Service

  • Product (Kits & Enzymes, Libraries, Design Tool, Antibodies, Others)
  • Service (Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis)

CRISPR and Cas Genes Market, By Application

  • Biomedical
  • Agricultural

CRISPR and Cas Genes Market, By End-use

  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations (CROs)

CRISPR and Cas Genes Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CRISPR and Cas Genes Market.

Available Customizations:

Global CRISPR and Cas Genes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CRISPR and Cas Genes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (Product (Kits & Enzymes, Libraries, Design Tool, Antibodies, Others), Service (Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA synthesis))
    • 5.2.2. By Application (Biomedical, Agricultural)
    • 5.2.3. By End-use (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations (CROs))
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America CRISPR and Cas Genes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Application
    • 6.2.3. By End-use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States CRISPR and Cas Genes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-use
    • 6.3.2. Canada CRISPR and Cas Genes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-use
    • 6.3.3. Mexico CRISPR and Cas Genes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-use

7. Europe CRISPR and Cas Genes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Application
    • 7.2.3. By End-use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany CRISPR and Cas Genes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-use
    • 7.3.2. France CRISPR and Cas Genes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-use
    • 7.3.3. United Kingdom CRISPR and Cas Genes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-use
    • 7.3.4. Italy CRISPR and Cas Genes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-use
    • 7.3.5. Spain CRISPR and Cas Genes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-use

8. Asia Pacific CRISPR and Cas Genes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Application
    • 8.2.3. By End-use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China CRISPR and Cas Genes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-use
    • 8.3.2. India CRISPR and Cas Genes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-use
    • 8.3.3. Japan CRISPR and Cas Genes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-use
    • 8.3.4. South Korea CRISPR and Cas Genes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-use
    • 8.3.5. Australia CRISPR and Cas Genes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-use

9. Middle East & Africa CRISPR and Cas Genes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Application
    • 9.2.3. By End-use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia CRISPR and Cas Genes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-use
    • 9.3.2. UAE CRISPR and Cas Genes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-use
    • 9.3.3. South Africa CRISPR and Cas Genes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-use

10. South America CRISPR and Cas Genes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Application
    • 10.2.3. By End-use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CRISPR and Cas Genes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-use
    • 10.3.2. Colombia CRISPR and Cas Genes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-use
    • 10.3.3. Argentina CRISPR and Cas Genes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global CRISPR and Cas Genes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Addgene
  • 15.3. Cellectis bioresearch Inc
  • 15.4. CRISPR Therapeutics Inc.
  • 15.5. Editas Medicine, Inc.
  • 15.6. F. Hoffmann-La Roche Ltd.
  • 15.7. Horizon Discovery Group plc
  • 15.8. Lonza Group AG
  • 15.9. GenScript Biotech Corporation
  • 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer